Health Canada approves Cystic Fibrosis drug

·2 min read

Health Canada as approved the drug Trikafta for sale in Canada.

Several local people have been working to have the drug approved to bring help to people with cystic fibrosis.

The national agency responsible for negotiating drug prices on behalf of provincial, territorial, and federal drug plans has agreed on pricing with the manufacturer of two other CF drugs – Kalydeco and Orkambi.

These transformational medications have proven to improve life quality and extend the lives of people living with cystic fibrosis.

Jim Wilson, MPP for Simcoe-Grey has been working with local families to have these drugs brought to Canada.

Much of the credit for this progress goes to families in our region who have fought long and hard for these life-saving drugs,” said Mr. Wilson in a statement. “I’ve been proud to work alongside people like Beth and Madi Vanstone, and Sasha Haughian and Jamie Larocque, who have been tireless in their efforts to access these innovative drugs that are available, and paid for by health plans, in many other countries.”

The announcement from Ottawa means that doctors can now prescribe Trikafta for people ages 12 and up with cystic fibrosis. The deal between the pan-Canadian Pharmaceutical Alliance and the drug manufacturer means that provincial governments can now negotiate agreements with Vertex Pharmaceuticals (Canada).

“The ball is now in Doug Ford's court,” Mr. Wilson said. “I am confident eh government of Ontario will live up to its promise to list these drugs on the Ontario Drug Benefit Formulary and quickly make them available to patients like 16 year-=old Finn Murphy of Collingwood who wants to get back to playing hockey.”

Mr. Wilson has raised the question of cystic fibrosis medication availability numerous times over the past ten years in the Ontario legislature.

Brian Lockhart, Local Journalism Initiative Reporter, New Tecumseth Times

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting